Photo of Jeffrey A. Gelfand, MD

Jeffrey A. Gelfand, MD


Accepting New Patients



Infectious Diseases


Clinical Interests
  • Babesiosis
  • Urinary tract infection
  • Fevers
  • Sepsis and Septic Shock
  • Infectious diseases
Medical Education
  • MD, Tufts University School of Medicine
  • Residency, The Johns Hopkins Hospital
  • Fellowship, National Institute of Health
Board Certifications
  • Infectious Disease
  • Internal Medicine
  • Allergy & Immunology
Foreign Languages
  • French
  • Boston: Massachusetts General Hospital
Insurances Accepted
  • Aetna Health Inc.
  • AllWays Health (NHP) - ACD
  • AllWays Health (NHP) - PBO
  • Beech Street
  • Blue Cross Blue Shield - Blue Care 65
  • Blue Cross Blue Shield - Indemnity
  • Blue Cross Blue Shield - Managed Care
  • Blue Cross Blue Shield - Partners Plus
  • BMC HealthNet Mass Health MCO/ACO
  • Cigna (PAL #'s)
  • Commonwealth Care Alliance
  • Fallon Community HealthCare
  • Great-West Healthcare (formally One Health Plan)
  • Harvard Pilgrim Health Plan - PBO
  • Health Care Value Management (HCVM)
  • Humana/Choice Care PPO
  • Maine Community Health Options (MCHO)
  • MassHealth
  • Medicare
  • Medicare - ACD
  • OSW - Maine
  • OSW - New Hampshire
  • OSW - Rhode Island
  • OSW - Vermont
  • Private Health Care Systems (PHCS)
  • Senior Whole Health
  • TriCare
  • Tufts Health Plan
  • Unicare
  • United Healthcare (non-HMO) - ACD
  • United Healthcare (non-HMO) - PBO
  • Well Sense Pediatrics

Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.

Patient Age Group
Provider Gender

News & Events

  • Creating hope from loss

    Inspired by his wife's memory, Jeffrey Gelfand, MD, and his MGH colleagues set out to create a vaccine to attack tumors in patients already diagnosed with cancer.

  • Novel cancer vaccine holds promise against ovarian cancer, mesothelioma

    A novel approach to cancer immunotherapy may provide a cost-effective weapon against some of the most deadly tumors, including ovarian cancer and mesothelioma. A protein engineered by MGH investigators to combine a molecule targeting a tumor antigen with an immune-function stimuating protein prolonged survival in animal models of both tumors.



Infectious Disease Associates
55 Fruit Street
Boston, MA 02114-2696
Phone 1: 617-724-0082
Phone 2: 617-726-1796
Fax: 617-726-7416

Back to Top